Page 64 - fbkCardioDiabetes_2017
P. 64

40                           Cardio Diabetes Medicine 2017





              ROLE OF ABPM IN DIABETIC PATIENTS          5,6
                - ABPM  is  advisable  in all  diabetic patients with
                high-normal BP
                - Diabetic patients are more likely to have
                - White-coat hypertension
                - Masked hypertension
                - Nondipping

                - Reverse dipping
                - Morning BP surge
                - High  prevalence of masked hypertension  in dia-
                betic patients are  associated with  higher  risk  of        Fig no:2 ABPM in Diabetes
                brain and kidney damage and possible  cardiac
                damage, which  further  increase  cardiovascular   TARGET BP IN DM
                complications.
                                                                   - Patients with no proteinuria  or  proteinuria  of  less
                - White-coat  hypertension  in diabetic patients ap-  than 1gmBP should be less than 130/80
                pears to be associated with a lower risk than sus-    - Patients with proteinuria  of  more  than  1gmBP
                tained hypertension.
                                                                   should be less than 125/75
                - Nondipping  and reverse  dipping  may reflect au-    - The  aim is  to maintain  low BP  which  patient can
                tonomic  dysfunction  and it might be used as a    tolerate without postural hypotension and without
                clinical marker of diabetic autonomic neuropathy.
                                                                   compromise on  critical  vascular  beds as well as
                - ABPM  provides  information on heart rate  at the   quality of life.
                time of BP measurements all over the  24  hours,
                and a rough estimate of heart rate variability. The  Effects of Drugs on Both Diseases Ideal anti-
                reduced heart rate variability is the  index of dia-  hypertensive drug in DM
                betic neuropathy.
                                                                   - Must decrease blood pressure to ≤ 130/80
                - ABPM  also provides information  on Pulse pres-    - Must reduce the RAAS activity, improve endothe-
                sure  (difference between systolic  and diastolic   lial dysfunction
                BP), when increased is considered as a surrogate
                marker of stiffening of arterial walls             - Must prevent, improve or arrest proteinuria

                                                                   - Must prevent and protect from CAD, CKD, CHF
                                                                   - Must be favorable on glycemic control
                                                                   - Must improve the dyslipidemia – not worsen it
                                                                   - Must not worsen peripheral arterial disease
                                                                   - Must not cause impotence

                                                                   - Must not decrease eGFR and increase serum cre-
                                                                   atinine
                                                                   - Must not increase uric acid, serum potassium
                                                                   - Can be easily combined with other drugs

                                                                   - An  ideal  agent should not increase  insulin resis-
                                                                   tance
                                                                   - Well tolerated, cost effective

                                                                 Effects of anti-hypertensives on diabetes

                                                                   - ACEIs and ARBsare suitable first line antihyperten-

                                                         GCDC 2017
   59   60   61   62   63   64   65   66   67   68   69